Cardiol Therapeutics Inc Class A (CRDL)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $127.69M
Last updated: Nov 17, 2026 at 11:04 AM ET
Cardiol Therapeutics Inc Class A (CRDL) Financials: Revenue, Profit and Cash Flow
Cardiol Therapeutics Inc Class A reported revenue of CAD 0 for the fiscal year ended Dec 31, 2025. That year, net income was CAD -33.82M, operating cash flow was CAD -23.85M and free cash flow was CAD -23.88M. The quarter ended Sep 30, 2026 had net income of CAD -12.98M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of CAD 34.32M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | 0 | N/A | N/A | N/A | N/A |
| Dec 2024 | 0 | N/A | N/A | N/A | N/A |
| Dec 2023 | 0 | N/A | N/A | N/A | N/A |
| Dec 2022 | 0 | -100.0% | N/A | N/A | N/A |
| Dec 2021 | 62.27K | -20.9% | -179.9% | -49092.4% | -40170.9% |
| Dec 2020 | 78.76K | N/A | -228.8% | -20620.3% | -20570.9% |
| Dec 2019 | 0 | N/A | N/A | N/A | N/A |
| Dec 2018 | 0 | N/A | N/A | N/A | N/A |
| Dec 2017 | N/A | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 62.27K | 78.76K | 0 | 0 | N/A |
| Cost of revenue | N/A | N/A | 187.38K | 162.23K | 174.26K | 180.17K | 116.11K | 91.49K | 53.34K |
| Gross profit | N/A | N/A | -187.38K | -162.23K | -112.00K | -180.17K | -116.11K | -91.49K | -53.34K |
| Research and development | 14.02M | 14.01M | 10.73M | 13.99M | 8.59M | 8.25M | 2.72M | 1.53M | 441.26K |
| Operating income | -34.32M | -40.28M | -22.47M | -30.49M | -30.57M | -16.24M | -10.89M | -7.39M | -1.59M |
| Net income | -33.82M | -36.68M | -21.22M | -22.82M | -25.01M | -16.20M | -10.55M | -15.89M | -1.66M |
| EBITDA | -33.72M | -36.30M | -20.97M | -22.60M | -24.79M | -15.97M | -10.40M | -7.30M | -1.50M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit | -12.45K | N/A | -26.78K | -25.95K | N/A | N/A | N/A | -33.70K | N/A | -45.24K | -61.62K | N/A |
| Operating income | -9.55M | -11.28M | -9.73M | -8.03M | -10.18M | -7.68M | -8.43M | -6.94M | -14.14M | -5.66M | -8.41M | -8.03M |
| Net income | -12.98M | -8.64M | -10.85M | -7.21M | -9.96M | -8.35M | -8.29M | -5.68M | -12.73M | -4.82M | -9.18M | -7.64M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of CAD 38.35K by 21.38M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 23.62M | 31.86M | 36.70M | 45.76M | 87.88M | 15.89M | 15.50M | 24.68M | 3.22M |
| Current assets | 23.50M | 31.67M | 36.15M | 45.32M | 87.14M | 14.95M | 14.37M | 24.03M | 2.48M |
| Cash and equivalents | 21.42M | 30.58M | 34.93M | 43.83M | 83.90M | 14.03M | 6.96M | 16.73M | 2.36M |
| Total liabilities | 5.74M | 7.14M | 8.45M | 7.25M | 11.64M | 2.62M | 830.83K | 2.41M | 366.76K |
| Short-term debt | 38.35K | 33.01K | 15.81K | 37.21K | 44.71K | 51.91K | 50.47K | N/A | N/A |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 269.22K | 190.04K |
| Shareholder equity | 17.88M | 24.73M | 28.25M | 38.51M | 76.24M | 13.27M | 14.67M | 22.27M | 2.85M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 33.00M | 29.37M | 31.49M | 23.62M | 12.95M | 19.94M | 25.45M | 31.86M | 17.52M | 26.31M | 31.13M | 36.70M |
| Total liabilities | 5.30M | 5.33M | 7.22M | 5.74M | 3.39M | 8.13M | 7.87M | 7.14M | 7.09M | 10.95M | 11.07M | 8.45M |
| Cash and equivalents | 29.33M | 26.09M | 27.74M | 21.42M | 11.62M | 18.20M | 23.29M | 30.58M | 15.89M | 24.02M | 28.57M | 34.93M |
| Shareholder equity | 27.70M | 24.04M | 24.27M | 17.88M | 9.56M | 11.81M | 17.59M | 24.73M | 10.43M | 15.36M | 20.06M | 28.25M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -23.85M | -25.06M | -25.18M | -27.22M | -23.55M | -9.13M | -11.38M | -10.89M | -1.29M |
| Capital expenditures | 24.48K | 21.29K | 64.31K | 74.71K | 12.92K | 40.60K | 424.31K | 13.79K | 29.17K |
| Free cash flow | -23.88M | -25.08M | -25.24M | -27.30M | -23.56M | -9.17M | -11.80M | -10.91M | -1.32M |
| Investing cash flow | -24.48K | -21.29K | -64.31K | -74.71K | -12.92K | -40.60K | -424.31K | -13.79K | -29.17K |
| Financing cash flow | 15.54M | 18.84M | -55.38K | -53.93K | 93.44M | 16.30M | 2.03M | 25.28M | 3.68M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -4.46M | -4.38M | -7.54M | -5.23M | -6.93M | -4.55M | -7.15M | -5.59M | -7.77M | -4.78M | -6.92M | -6.46M |
| Capital expenditures | 23.97K | 3.03K | 47.71K | 3.09K | 3.02K | 6.44K | 11.94K | 6.16K | 7.87K | 3.80K | 3.46K | 10.71K |
| Free cash flow | -4.48M | -4.38M | -7.58M | -5.23M | -6.93M | -4.56M | -7.17M | -5.60M | -7.78M | -4.78M | -6.93M | -6.48M |
Frequently Asked Questions About CRDL
What is Cardiol Therapeutics Inc Class A's annual revenue?
Cardiol Therapeutics Inc Class A reported revenue of CAD 0 for the fiscal year ended Dec 31, 2025.
Is Cardiol Therapeutics Inc Class A profitable?
No. Cardiol Therapeutics Inc Class A reported net income of CAD -33.82M for the fiscal year ended Dec 31, 2025.
How much free cash flow does CRDL generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of CAD -23.85M minus capital expenditures of CAD 24.48K produced free cash flow of CAD -23.88M.
How much debt does Cardiol Therapeutics Inc Class A have?
The balance sheet dated Dec 31, 2025 reported short-term debt of CAD 38.35K and cash and equivalents of CAD 21.42M.
CRDL pages: Overview, Financials, Competitors